[1]杨晴 梁岩.非维生素K拮抗剂口服抗凝药物治疗心室附壁血栓形成的探究[J].心血管病学进展,2021,(3):198-201,206.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.002]
　YANG Qing,LIANG Yan.Investigation of Non-vitamin K Antagonist Oral Anticoagulants for Treatment of Ventricular Thrombosis[J].Advances in Cardiovascular Diseases,2021,(3):198-201,206.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.002]
点击复制

非维生素K拮抗剂口服抗凝药物治疗心室附壁血栓形成的探究()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年3期
页码:
198-201,206
栏目:
出版日期:
2021-03-25

文章信息/Info

Title:
Investigation of Non-vitamin K Antagonist Oral Anticoagulants for Treatment of Ventricular Thrombosis
作者:
杨晴 梁岩
(中国医学科学院 北京协和医学院阜外医院急重症中心,北京100037)
Author(s):
YANG Qing;  LIANG Yan
(Emergency Center,Fuwai Hospital,CAMS & PUMC,Beijing 100037,China)
关键词:
心室附壁血栓; 非维生素K拮抗剂; 口服抗凝药物
Keywords:
Ventricular thrombosis; Non-vitamin K antagonist; Oral anticoagulants
DOI:
10.16806/j.cnki.issn.1004-3934.2021.03.002
摘要:
心室附壁血栓最常见于左心室，常发生于心肌梗死后。对发生心室附壁血栓的患者，虽无明确的指南推荐抗凝药物的选择，在临床上仍普遍应用华法林治疗。然而，由于华法林本身存在一定的局限性，患者的依从性往往不佳。非维生素K拮抗剂口服抗凝药物（NOACs）以起效快、不易受食物及药物的影响、具有较稳定的抗凝活性、无需频繁实验室监测的特点而被尝试作为治疗心室附壁血栓的替代药物。到目前为止，NOACs对心室附壁血栓形成的治疗作用尚无大型随机对照试验的结果。现就NOACs治疗心室附壁血栓的有效性和安全性进行阐述。国内外研究和指南显示，应用NOACs治疗后血栓完全消退率高，血栓栓塞或出血并发症发生率低，故NOACs（包括Xa因子抑制剂和直接凝血酶抑制剂）可能是治疗心室附壁血栓的不错选择，尤其是对于不适合华法林抗凝的患者，临床医师可根据患者个体情况有指征地选择NOACs进行抗凝治疗，从而缩短患者住院时间，减少并发症，提高生活满意度。
Abstract:
Ventricular thrombus is most common in the left ventricle and often occurs after myocardial infarction. Although there are no clear guidelines recommending the choice of anticoagulant for patients with ventricular thrombosis, warfarin is still commonly used in clinical practice. However, due to the limitations of warfarin,patients’ compliance is often poor. Non-vitamin K antagonist oral anticoagulants(NOACs) have been attempted as an alternative drug for the treatment of ventricular thrombus because of its rapid onset of action, fewer interaction with food and medications, more stable anticoagulation activity and the no need of frequent laboratory monitoring. So far, there is no large randomized controlled trial on the therapeutic effect of NOACs on ventricular thrombosis.This article _____________________________________通信作者：梁岩，E-mail: fwliangyan@163.comreviews the efficacy and safety of NOACs in the treatment of ventricular thrombus. Studies and guidelines at home and abroad show that the complete regression rate of thrombus is high and the incidence of thromboembolism or bleeding complications is low after treatment with NOACs. Therefore, NOACs (including Xa factor inhibitors and direct thrombin inhibitors) may be a good choice for the treatment of ventricular thrombus,providing clinicians with alternative anticoagulation therapy for individual patients,especially those who are not suitable for warfarin anticoagulation,thus shortening the length of hospital stay,reducing complications,and improving life satisfaction.

参考文献/References:

[1] Jiang YX,Jing LD,Jia YH. Clinical characteristics and risk factors of left ventricular thrombus after acute myocardial infarction:a matched case-control study[J]. Chin Med J(Engl),2015,128(18):2415-2419.

[2] Akdis D,Chen K,Saguner AM,et al. Clinical characteristics of patients with a right ventricular thrombus in arrhythmogenic right ventricular cardiomyopathy[J]. Thromb Haemost,2019,119(8):1373-1378.

[3] Lee JM,Park JJ,Jung HW,et al. Left ventricular thrombus and subsequent thromboembolism,comparison of anticoagulation,surgical removal,and antiplatelet agents[J]. J Atheroscler Thromb,2013,20(1):73-93.

[4] Delewi R,Zijlstra F,Piek JJ. Left ventricular thrombus formation after acute myocardial infarction[J]. Heart,2012,98(23):1743-1749.

[5] Gianstefani S,Douiri A,Delithanasis I,et al. Incidence and predictors of early left ventricular thrombus after ST-elevation myocardial infarction in the contemporary era of primary percutaneous coronary intervention[J]. Am J Cardiol,2014,113(7):1111-1116.

[6] Turpie AG,Robinson JG,Doyle DJ,et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction[J]. N Engl J Med,1989,320(6):352-357.

[7] Caldeira D,Costa J,Ferreira JJ,et al. Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation:systematic review and meta-analysis[J]. Clin Res Cardiol,2015,104(7):582-590.

[8] Albaeni A,Chatila K ,Beydoun HA,et al. In-hospital left ventricular thrombus following ST-elevation myocardial infarction[J]. Int J Cardiol,2020,299:1-6.

[9] Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology(ESC),Steg PG,James SK,et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J]. Eur Heart J,2012,33(20):2569-2619.

[10] O’Gara PT,Kushner HG ,Ascheim DD ,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol,2013,61(4):485-510.

[11] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2015)[J]. 中华心血管病杂志,2015,43(5):380-393.

[12] Connolly SJ,Ezekowitz MD,Yusuf S,et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med,2009,361(12):1139- 1151.

[13] Kearon C,Akl EA,Ornelas J,et al. Antithrombotic therapy for VTE disease:CHEST guideline and expert panel report[J]. Chest,2016,149(2):315- 352.

[14] Lip GY,Hammerstingl C,Marin F,et al. Left atrial thrombus resolution in atrial fibrillation or flutter:results of a prospective study with rivaroxaban(X-TRA) and a retrospective observational registry providing baseline data(CLOT-AF)[J]. Am Heart J,2016,178:126- 134.

[15] Orenes-Pi?ero E,Esteve-Pastor MA,Valdés M,et al. Efficacy of non-vitamin-K antagonist oral anticoagulants for intracardiac thrombi resolution in nonvalvular atrial fibrillation[J]. Drug Discov Today,2017,22 (10):1565-1571.

[16] Kemcn WN,Ovbiagele B,Black HR. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack:a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke,2014,45(7):216-236.

[17] Ibanez B,James S,Agewall S,et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC)[J]. Eur Heart J,2018,39(2):119-177.

[18] Changela J,Anwar M. Rivaroxaban treatment for left ventricular thrombus[J]. Can J Hosp Pharm,2019,72(3):245-248.

[19] Eikelboom?JW,Connolly SJ,Bosch J,et al. Rivaroxaban with or without aspirin in stable cardiovascular disease[J]. N Engl J Med,2017,377(14):1319-1330.

[20] Abdelnaby M,Almaghraby A,Abdelkarim O,et al. The role of rivaroxaban in left ventricular thrombi[J]. Anatol J Cardiol,2019,21(1):47-50.

[21] Leow AS,Sia CH,Tan BY,et al. A meta-summary of case reports of non-vitamin K antagonist oral anticoagulant use in patients with left ventricular thrombus[J]. J Thromb Thrombolysis,2018,46(1):68-73.

[22] Smetana KS,Dunne J,Parrott K,et al. Oral factor Xa inhibitors for the treatment of left ventricular thrombus:a case series.[J]. J Thromb Thrombolysis,2017,44(4):519-524.

[23] Azizi A,Puricel S,Cook S,et al. Rivaroxaban dissolves postinfarction left ventricular thrombus[J]. Cardiovasc Med,2016,19(1):25-27.

[24] Granger CB,Alexander JH,McMurray JJ,et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med,2011,365(11):981-992.

[25] Ghaffarpasand E,Tehrani MD,Marszalek J,et al. Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis[J]. J Thromb Thrombolysis,2018,46(3):332-338.

[26] Mano Y,Koide K,Sukegawa H,et al. Successful resolution of a left ventricular thrombus with apixaban treatment following acute myocardial infarction[J]. Heart Vessels,2016,31(1):118-123.

[27] Berry A,Brancheau D,Zughaib M. Rapid resolution of left ventricular thrombus with apixaban therapy[J]. SAGE Open Med Case Rep,2017,5:2050313X17745211.

[28] Ammollo CT,Semeraro F ,Incampo F ,et al. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor[J]. J Thromb Haemost,2010,8(4):790-798.

[29] Cui J,Du X,Wu JH,et al. Effect of non-vitamin K antagonist oral anticoagulants on left atrial or atrial appendage thrombi in patients with nonvalvular atrial fibrillation[J]. Zhonghua Xin Xue Guan Bing Za Zhi,2018,46(8):606-610.

[30] Kajy M,Shokr M,Ramappa P. Use of direct oral anticoagulants in the treatment of left ventricular thrombus:systematic review of current literature[J].?Am J Ther,2020,27(6):e584-e590.

[31] Nagamoto Y,Shiomi T,Matsuura T,et al. Resolution of a left ventricular thrombus by the thrombolytic action of dabigatran[J]. Heart Vessels,2014,29(4):560-562.

[32] Yamamoto T,Konishi T,Funayama N,et al. Resolution of left ventricular thrombus after dabigatran therapy in two patients with old anteroseptal myocardial infarction[J]. Cardiol Pharmacol,2015,4:152.

[33] Daher J, da Costa A, Hilaire C,et al. Management of left ventricular thrombi with direct oral anticoagulants:retrospective comparative study with vitamin K antagonists[J]. Clin Drug Investig,2020,40(4):343-353.

[34] Jumeau C,Rupin A,Chieng-Yane P,et al. Direct thrombin inhibitors prevent left atrial remodeling associated with heart failure in rats.[J]. JACC Basic Transl Sci,2016,1(5):328-339.

更新日期/Last Update: 2021-05-27